Analyst: Big Opportunities Coming In Medical Device Space

Share This Article
February 24, 2017 7:45am NYSE:XHE

Medical Device

From The Gold Report: The stage has been set for high levels of uncertainty, and with uncertainty comes opportunities in commodities, posits Lior Gantz, editor of Wealth Research Group, who also sees opportunities in disruptive technologies in the medical arena.


US YOY Inflation Rate

This has been the most important week of 2017.

The trends that are now in motion will set the tone for the entire year, and there are critical statistics to align with.

Back in 2012, when Obama was in office, inflation rates were at 2.5%, precious metals stocks were extremely overvalued, gold was priced at $1,800 per ounce, and Europe and China were slowing down.

10 Year Gold Price

Today, after a five-year downtrend, gold has begun moving higher since 2016.

Four consecutive down years in a sector has only occurred 1% of the time since the 1920s, and five down years has almost never occurred.

Gold Appreciates on Negative Treasury Yield

Uranium and coal are also up substantially after five and six years of downtrends.

Going back to the 1920s, here’s the data Wealth Research Group found on fortunes earned for investors on down year trends:

Down Years

Today presents a rare opportunity in commodities.

What is truly a fundamentally essential key to understand is that today’s investing environment is unique. On one end, inflation is rising in the U.S. while interest rates are rising, which means that lending is going to pick up steam. This is all while the new president, who is pro-business, is creating uncertainty in foreign relations.

Uncertainty Is Soaring

This is a genuinely useful chart, as it points out loud and clear all the fundamental reasons for which gold and silver prices will continue higher.

Uncertainty, coupled with the rising inflation that keeps real rates negative, is the ultimate environment for gold—Fed tightening periods have been wealth-generating moments in the past and are going to be so once more.

This week, Germany has finished repatriation of 300 tons of gold bars from the United States.

Germany’s central bank has established the return of its gold reserves to domestic vaults by the end of 2017, three years ahead of schedule.

Not only Germany (the only European superpower) left, taking drastic political measures with its reserves, but China, the new global force, is also dumping treasuries at an alarming speed.

China's Central Bank Sticks with Bullion

No financial analysts from global hedge funds to private equity are noticing an unprecedented phenomenon—Wealth Research Group is the only financial newsletter pointing out this divergence. Governments are now exhibiting high uncertainty, while the business sector is astonishingly optimistic.

There’s a record-breaking amount of cash waiting to be invested today, and the biggest buyers with the deepest pockets are large financial institutions and big pharma.

The majority of my contacts in the pharmaceutical industry have told me that managements now have an “open checkbook” and should be looking at two types of companies:

1. Patent-Based Disruptive Technologies: A company that displaces an established technology and shakes up the industry or a groundbreaking product that creates a completely new industry.

2. Personalized Medicine: Tailoring of medical treatment to the individual characteristics of each patient. The approach relies on scientific breakthroughs in the understanding of how a person’s unique molecular and genetic profile makes them susceptible to certain diseases.

This same research is increasing our ability to predict which medical treatments will be safe and effective for each patient and which ones will not be.

Personalized Medicine

The baby boomers are indeed approaching their 60s, but they are spending a fortune on making sure they stay young and vital physically.

Personalized medicine small-cap companies are exactly what cash-rich big pharma wants because these are high-margin businesses with patented intellectual property, which gives them a competitive advantage.

2017 is a unique year to invest. Commodities have turned higher for the first time in five years, and cutting-edge technologies are hunted for by mega-wealthy multinational corporations.

Trump’s administration is going to continue to make it easier for deals to materialize.

Investing in the future by positioning now is the formula for investing in disruptive technologies in the medical arena, and companies that sincerely strive to improve lives will flourish.

The SPDR Series Trust (NYSE:XHE) was unchanged in premarket trading Friday. Year-to-date, XHE has gained 10.13%, versus a 5.78% rise in the benchmark S&P 500 index during the same period.

XHE currently has an ETF Daily News SMART Grade of A (Strong Buy), and is ranked #18 of 36 ETFs in the Health & Biotech ETFs category.


This article is brought to you courtesy of The Gold Report.


Read Next


Get Free Updates

Join over 50,000 investors who get the latest news from ETFDailyNews.com!

Most Popular


From Our Partners


Explore More from ETFDailyNews.com

Free Daily Newsletter

Get daily ETF insights from our market experts. Never miss another important market development again!

ETFDailyNews.com respects your privacy.

Best ETFs

We've rated and ranked nearly 2,000 ETFs and ETNs using our proprietary SMART Grade system.

View Top Rated ETFs

Best Categories

We've ranked dozens of ETF categories based on relative performance.

Best ETF Categories